Capsular polysaccharide-amikacin nanoparticles for improved antibacterial and antibiofilm performance

Abstract

Natural nanoscale polysaccharide and its application have attracted much attention in recent years. In this study, we report for the first time that a novel naturally occurring capsular polysaccharide (CPS-605) from Lactobacillus plantarum LCC-605, which can self-assemble into spherical nanoparticles with an average diameter of 65.7 nm. To endow CPS-605 with more functionalities, we develop amikacin-functionalized capsular polysaccharide (CPS) nanoparticles (termed CPS-AM NPs) with improved antibacterial and antibiofilm activities against both Escherichia coli and Pseudomonas aeruginosa. They also exhibit faster bactericidal activity than AM alone. The high local positive charge density of CPS-AM NPs facilitates the interaction between the NPs and bacteria, leading to extraordinary bactericidal efficiencies (99.9 % and 100 % for E. coli and P. aeruginosa, respectively, within 30 min) by damaging the cell wall. Very interestingly, CPS-AM NPs exhibit an unconventional antibacterial mechanism against P. aeruginosa, that is, they can induce plasmolysis, along with bacterial cell surface disruption, cell inclusion release and cell death. In addition, CPS-AM NPs exhibit low cytotoxicity and negligible hemolytic activity, showing excellent biocompatibility. The CPS-AM NPs provide a new strategy for the design of next-generation antimicrobial agents that can reduce the working concentration of antibiotics to fight against bacterial resistance.

Keywords: Antibacterial; Antibiofilm; Antibiotic; Capsular polysaccharide; Nanoparticles; Plasmolysis.